A new CRISPR-based one-off procedure that lowers “bad” cholesterol is expected to enter Phase I human trial in 2026. If successful, it could be the first approved genetic-silencing method on the market, replacing the need for long-term medication and slashing…
Continue reading with a subscription
This article is available to subscribers. Subscribe to read it in full, or sign in if you already have an account.